A stealthy start­up is lever­ag­ing nat­ur­al killer cells with 'mem­o­ry-like' abil­i­ties to go af­ter blood can­cer and be­yond

The promise of next-gen, “off-the-shelf” cell ther­a­pies have thor­ough­ly en­tranced bio­phar­ma with the promise of low­er­ing man­u­fac­tur­ing costs and po­ten­tial­ly chal­leng­ing dom­i­nant check­point in­hibitors. But to get there, com­pa­nies need a po­tent ther­a­py and one that can be con­tin­u­ous­ly sourced from donors.

A new biotech un­cloak­ing from a lengthy de­vel­op­ment pe­ri­od thinks it may have solved that puz­zle.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER